Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 9/20 | 0.35 |
| ▸ | MMP3 | P08254 | 8/20 | 0.35 |
| ▸ | MMP13 | P45452 | 8/20 | 0.35 |
| ▸ | MMP1 | P03956 | 7/20 | 0.35 |
| ▸ | MMP7 | P09237 | 7/20 | 0.35 |
| ▸ | MMP9 | P14780 | 7/20 | 0.35 |
| ▸ | ADAMTS4 | O75173 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | MMP14 | P50281 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28757910 | 1.00 | CA2 (0.40) | CA2CA1TP53KDM4EMMP2 | |
| SCHEMBL3529081 | 1.00 | CA2 (0.40) | CA2CA1TP53KDM4EMMP2 | |
| SCHEMBL5839738 | 0.84 | KDM4E (0.49) | KDM4EMMP2MMP3MMP13MMP1 | |
| SCHEMBL5839741 | 0.84 | KDM4E (0.49) | KDM4EMMP2MMP3MMP13MMP1 | |
| SCHEMBL29573798 | 0.82 | CA2 (0.40) | CA2CA1TP53KDM4EMMP2 | |
| SCHEMBL19545557 | 0.81 | MME (0.39) | CA2CA1ADAMTS4 | |
| SCHEMBL19520960 | 0.78 | CA14 (0.39) | CA2CA1TP53KDM4EMMP2 | |
| SCHEMBL19520958 | 0.78 | CA14 (0.39) | CA2CA1TP53KDM4EMMP2 | |
| SCHEMBL3154122 | 0.77 | ALDH1A1 (0.52) | CA2CA1 | |
| SCHEMBL3154117 | 0.77 | ALDH1A1 (0.52) | CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645771-B2 | CCR5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORP. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | SMITHKLINE BEECHAM CORPORATION | 2006-10-12 | — | — | US | disclosed |
| CN-1744899-A | Piperidine derivatives as CCR5 antagonists | SMITHKLINE BEECHAM CORP (US) | 2006-03-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229336-A1 | Ccr5 antagonists as therapeutic agents | CCR5, CCR1, CXCR3 | CA2 4267/4885CA1 4808/4885TP53 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.